Last month, several of the world’s leading experts in leptomeningeal metastases (LM) came together at the American Society of Clinical Oncology (ASCO) / Society for Neuro-Oncology (SNO) CNS Metastases Conference to share insights, research, and clinical updates on this challenging condition.
The session featured a presentation and panel discussion that highlighted:
- The latest advances in LM diagnosis and treatment
- Ongoing clinical trial opportunities
- The importance of collaboration across research, diagnostics, and patient care
Watch the full video recording of the presentation here.
Why Leptomeningeal Metastases Research Matters
Leptomeningeal metastases remain a devastating complication of advanced cancers, affecting the central nervous system and significantly impacting patient outcomes. With limited treatment options available today, advancing research, clinical trials, and innovative diagnostics is critical to improving care for LM patients.
Looking Ahead
The strong interest and participation at the SNO/ASCO CNS Metastases Conference demonstrate the growing commitment to tackling LM through research, collaboration, and patient-focused innovation.
Stay connected with us for updates on future events, clinical data, and ongoing progress in neuro-oncology and CNS cancer research.
#LeptomeningealMetastases #LM #NeuroOncology #BrainCancer #CNSMetastases #ClinicalTrials #CancerResearch #OncologyInnovation #ASCO #SNO #SNOASCO2025
Recent Comments